Li L - Search Results

1

Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.

Liu C, Li L, Gao F, Zhou J, Qin Y, Yuan X, Yang G, Zhu Y. Liu C, et al. Among authors: li l. Front Bioeng Biotechnol. 2022 Jun 17;10:928169. doi: 10.3389/fbioe.2022.928169. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35782491 Free PMC article.

2

MiR-2861 Behaves as a Biomarker of Lung Cancer Stem Cells and Regulates the HDAC5-ERK System Genes.

Zhao M, Li L, Zhou J, Cui X, Tian Q, Jin Y, Zhu Y. Zhao M, et al. Among authors: li l. Cell Reprogram. 2018 Apr;20(2):99-106. doi: 10.1089/cell.2017.0045. Epub 2018 Mar 13. Cell Reprogram. 2018. PMID: 29620443

3

Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity.

Zhou Y, Li L, Yu Z, Gu X, Pan R, Li Q, Yuan C, Cai F, Zhu Y, Cui Y. Zhou Y, et al. Among authors: li l, li q. Pediatr Allergy Immunol. 2022 Aug;33(8):e13835. doi: 10.1111/pai.13835. Pediatr Allergy Immunol. 2022. PMID: 36003049

4

Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress.

Qin Y, Meng X, Li L, Liu C, Gao F, Yuan X, Huang Y, Zhu Y. Qin Y, et al. Among authors: li l. Eur J Pharmacol. 2023 Dec 5;960:176144. doi: 10.1016/j.ejphar.2023.176144. Epub 2023 Oct 20. Eur J Pharmacol. 2023. PMID: 37866745

5

The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy.

Liu C, Wang Q, Li L, Gao F, Zhang Y, Zhu Y. Liu C, et al. Among authors: li l. Int J Pharm. 2024 Sep 30;663:124558. doi: 10.1016/j.ijpharm.2024.124558. Epub 2024 Aug 5. Int J Pharm. 2024. PMID: 39111352

6

Discovery of novel heteroaryl alkynes for highly potent KIT^D816V cells inhibition to treat gastrointestinal stromal tumors.

Xie Z, Li L, Guo Y, Zhang M, Chen T, Li Y, Li X, Zhu X, Zhang Y, Lou L, Hu Y. Xie Z, et al. Among authors: li y, li x, li l. Acta Pharm Sin B. 2022 Oct;12(10):4004-4007. doi: 10.1016/j.apsb.2022.07.015. Epub 2022 Aug 3. Acta Pharm Sin B. 2022. PMID: 36213539 Free PMC article. No abstract available.

7

Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.

Li L, Huang W, Ren X, Wang Z, Ding K, Zhao L, Zhang J. Li L, et al. Sci China Life Sci. 2024 Dec;67(12):2603-2616. doi: 10.1007/s11427-024-2685-9. Epub 2024 Aug 12. Sci China Life Sci. 2024. PMID: 39145866 Review.

8

Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.

Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Li Y, et al. Among authors: li l. Am J Cancer Res. 2023 Jan 15;13(1):161-175. eCollection 2023. Am J Cancer Res. 2023. PMID: 36777513 Free PMC article.

9

TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.

Wang L, Zhu X, Li L, Li L, Fu L, Li Y, Fu H, Chen X, Lou L. Wang L, et al. Among authors: li y, li l. Am J Cancer Res. 2021 Apr 15;11(4):1632-1645. eCollection 2021. Am J Cancer Res. 2021. PMID: 33948378 Free PMC article.

10

PDDA-Assisted Synthesis of Magnetic Fluorescent Fe₃O₄@SiO₂-CQD Composites.

Li L, Wang H, Fang J. Li L, et al. Langmuir. 2024 Dec 25. doi: 10.1021/acs.langmuir.4c03839. Online ahead of print. Langmuir. 2024. PMID: 39722162

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98,960 results

Search Page

Filters